iDEL Therapeutics Secures Seed Funding
iDEL Therapeutics, a biotech firm based in Dortmund, Germany, has successfully raised €9 million in a seed funding round. The company is developing a new class of cancer medicines that deliver therapeutic payloads directly into the cytosol of tumor cells, using a unique pan-cancer uptake mechanism.
Investment Details
The funding round was led by BiomedVC, with additional participation from NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II. This financial boost will support the company's efforts to progress its oncology pipeline, which is built on its proprietary direct cytosolic transfer technology.
Leadership and Vision
iDEL Therapeutics was co-founded by Marcus Kostka, Andreas Briel, and Jürgen Moll, who serve as the Chief Executive Officer, Chief Technology Officer, and Chief Scientific Officer, respectively. CEO Marcus Kostka commented on the funding, saying, "iDEL Therapeutics’ concept to unlock new cancer treatments represents an exciting new opportunity with the potential to significantly impact the oncology landscape."
Use of Funds
The newly acquired funds will be used to advance iDEL Therapeutics' two lead programs towards clinical evaluation. These programs aim to address a range of solid tumors using the company’s proprietary shuttling technology. This technology enables the evasion of endosomal entrapment and prevents the degradation of the transported compound, which is crucial for the effective delivery of large molecules, such as antibodies.
Innovative Technology
iDEL Therapeutics' approach is notable for its compatibility with both large and small molecules, targeting historically undruggable intracellular targets. This broadens the therapeutic windows across various cancer indications, potentially offering new treatment avenues for patients.
Future Outlook
With the support of its investors, iDEL Therapeutics is poised to make significant strides in the field of oncology, leveraging its innovative platform to develop treatments that could change the way cancer is treated. As the company moves forward, it will focus on refining its technology and preparing its lead candidates for clinical trials.